Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. The company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Shanghai, CN
Size (employees)
30 (est)-3%
Hua Medicine was founded in 2010 and is headquartered in Shanghai, CN
Report incorrect company information

Key People/Management at Hua Medicine

Li Chen

Li Chen

President and CEO

Hua Medicine Office Locations

Hua Medicine has an office in Shanghai and Pudong Xinqu
Pudong Xinqu, CN (HQ)
Cailun Rd
Pudong Xinqu, CN
Ai Di Sheng Lu
Show all (3)
Report incorrect company information

Hua Medicine Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$125 m

Latest funding size

$50 m

Time since last funding

2 years ago


Hua Medicine's latest funding round in April 2016 was reported to be $50 m. In total, Hua Medicine has raised $125 m
Report incorrect company information

Hua Medicine News and Updates

MOVES-China's Hua Medicine appoints BAML banker as new CFO ahead of listing

HONG KONG, Dec 22 (Reuters) - Chinese drug developer Hua Medicine has appointed George Lin, a veteran Bank of America Merrill Lynch banker as its chief financial officer, as it seeks to go public in the next 12 to 18 months.
Report incorrect company information